Fig. 2.

Identification of neoantigens: Tumor-specific mutations are identified using whole-exome sequencing (WES), confirmed by RNA sequencing, then ranked by predicted affinity binding to HLA types; finally, neoantigens are synthesized based on mutated alleles followed by ex vivo T-cell reactivity analysis to confirm the immunogenicity.